November 15, 2026 · JAMA · DOI: 10.1001/jama.2026.23420

Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial.

Listen to this summary

In this phase 3 randomized, double-blind trial, the authors asked whether once-weekly tirzepatide, added to lifestyle intervention, would safely reduce BMI in adolescents aged 12 to under 18 with obesity or overweight plus at least one obesity-related complication. Among 160 participants followed for 72 weeks, tirzepatide produced an 18.5% BMI reduction versus a 0.5% increase with placebo (estimated difference -19.0 percentage points), with 79.6% of treated patients achieving at least a 5% BMI reduction. The most common adverse events were mild-to-moderate gastrointestinal effects.

Aaron S Kelly, Karthik Chandrasekhar Pamidipati, Marianna Rachmiel, Gitanjali Srivastava, Daniel S Hsia, Claudia K Fox, Erika Fortes, Lisa McLeod, Madhumita Murphy, Apurva Prakash

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play